Laurus Labs, a pharmaceutical company, saw its shares surge 6% to a record high of ₹1,162.70 following the release of its Q4FY26 results. The company reported revenues of ₹1,812 crore, reflecting a 5% growth compared to the same quarter last year, and an EBITDA of ₹523 crore, which is a 10% increase. The EBITDA margins stood strong at 28.9%, supported by operational leverage and a favorable product mix. For the fiscal year 2025-2026, Laurus achieved a 23% year-on-year growth in revenue, totaling ₹6,813 crore, and a 64% increase in EBITDA to ₹1,826 crore, resulting in 26.8% margins. The growth in the Contract Development and Manufacturing Organization (CDMO) segment, which saw a 38% increase year-on-year, has been pivotal for the company, contributing significantly to its overall performance. Analysts from ICICI Securities and Motilal Oswal Financial Services have expressed optimism about Laurus' future, with a target price of ₹1,280 based on its growth trajectory and strategic investments in CDMO and new technologies.